scPharmaceuticals, Inc.
12
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
8.3%
1 terminated/withdrawn out of 12 trials
91.7%
+5.2% vs industry average
17%
2 trials in Phase 3/4
55%
6 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers
Role: lead
Furoscix in Heart Failure Patients With Diuretic Resistance
Role: collaborator
Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study
Role: lead
Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure
Role: lead
Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure
Role: lead
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
Role: lead
Product Design Clinical Performance Study of sc2Wear Furosemide Combination Product
Role: lead
Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration
Role: lead
Sub-Q Versus IV Furosemide in Acute Heart Failure
Role: collaborator
Pilot Study for First Clinical Use of sc2Wear Furosemide Combination Product
Role: lead
Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone Administration
Role: lead
A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen
Role: collaborator
All 12 trials loaded